Rival BTK degraders face off in CLL patients naive to BTK inhibition.
ApexOnco Front Page
Recent articles
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
The company’s pivotal trial is now set to start in the second half of 2025, from year-end 2024 previously.
Meanwhile, Lilly gets in on the next-gen KRAS action.
Gilead came out swinging in second-line lung cancer, but it might have just whiffed.
The PD-1 x VEGF bispecific apparently bests Keytruda, but questions remain.
Paloma-3 data suggest subcutaneous Rybrevant might have an edge over the intravenous formulation.
But will the FDA accept the surrogate endpoint used in ASC4First?